Skip to main content
. 2020 Jun;8(12):741. doi: 10.21037/atm-19-4728

Table S1. Clinical characteristics of the studied subjects.

Characteristics Discovery cohort Validation cohort Combined cohort
CAD (n=30) Control (n=30) P CAD (n=300) Control (n=179) P CAD (n=330) Control (n=209) P
Male, n (%) 29 (98.7) 27 (90.0) 0.605c 208 (69.3) 123 (68.7) 0.887c 237 (71.8) 150 (71.8) 0.990c
Age, years 58.2±3.4 57.8±4.0 0.089a 61.3±11.3 62.5±9.9 0.025a 60.9±10.9 61.9±9.4 0.308a
BMI, kg/m2 24.5±2.9 24.2±2.1 0.620a 25.1±3.4 24.3±1.9 <0.0001a 25.1±3.6 24.3±1.9 0.006a
Smoking, n (%) 24 (80.0) 16 (53.3) 0.028c 165 (55.0) 43 (24.0) <0.0001c 189 (57.3) 59 (28.2) <0.0001c
Alcoholism, n (%) 9 (30.0) 6 (20.0) 0.371c 74 (24.7) 28 (15.6) 0.020c 83 (25.2) 34 (16.3) 0.015c
Hypertension, n (%) 14 (46.7) 9 (30.0) 0.184c 191 (63.7) 57 (31.8) <0.0001c 206 (62.4) 66 (31.6) <0.0001c
Hyperlipidemia, n (%) 7 (23.3) 5 (16.7) 0.519c 62 (20.7) 20 (11.2) 0.008c 68 (20.6) 25 (12.0) 0.010c
T2DM, n (%) 8 (26.7) 6 (20.0) 0.542c 85 (28.3) 26 (14.5) 0.001c 92 (27.9) 32 (15.3) 0.001c
FPG, mmol/L 7.14 (5.99, 9.16) 5.44±0.39 <0.0001b 6.32 (5.39, 8.85) 5.19±0.57 <0.0001b 6.39 (5.42, 8.86) 5.24 (4.98, 5.57) <0.0001b
TC, mmol/L 4.08±1.11 4.42±0.46 0.001a 4.13 (3.37, 4.74) 4.36±0.53 <0.0001b 4.12 (3.37, 4.74) 4.49 (4.01, 4.80) <0.0001b
TG, mmol/L 1.75 (1.02, 2.25) 1.04±0.37 0.005b 1.46 (1.07, 2.16) 1.13±0.30 <0.0001b 1.47 (1.07, 1.18) 1.13 (0.85, 1.39) <0.0001b
HDL-C, mmol/L 0.97±0.28 1.58±0.34 <0.0001a 1.00 (0.86, 1.19) 1.53±0.33 <0.0001b 0.99 (0.85, 1.18) 1.47 (1.28, 1.75) <0.0001b
LDL-C, mmol/L 2.41±0.79 2.75±0.41 0.010a 2.40 (1.86, 2.88) 2.70±0.51 <0.0001b 2.40 (1.86, 2.87) 2.78 (2.42, 3.09) <0.0001b
WBC, 109/L 8.97±2.99 6.52±1.86 <0.0001a 7.46 (5.83, 9.57) 6.14±1.54 <0.0001b 7.63 (5.98, 9.88) 6.1 (5.11, 7.00) <0.0001b
NEU, 109/L 6.43±3.19 3.75±1.58 <0.0001a 5.14 (3.80, 8.20) 3.46±1.16 <0.0001b 5.01 (3.72, 7.38) 3.35 (2.63, 4.00) <0.0001b
LYM, 109/L 1.75±0.62 2.10±0.75 0.054a 1.53 (1.17, 2.17) 2.01±0.62 <0.0001b 1.50 (1.14, 2.01) 1.99 (1.55, 2.42) <0.0001b
MON, 109/L 0.64±0.27 0.49±0.18 0.015a 0.52 (0.42, 0.70) 0.46±0.14 0.001b 0.52 (0.42, 0.67) 0.46 (0.36, 0.59) <0.0001b
PLT, 109/L 230±90 185±40 0.043a 199 (156, 233) 182±50 0.040b 191.60 (158.3, 234.2) 177 (149, 220) 0.003b
CRP, mg/L 4.22 (1.06, 12.50) 2.74 (0.95, 7.75) 2.98 (0.98, 8.33)
NT-proBNP, pg/mL 372 (147, 565) 371 (105, 1,107) 372.3 (107.25, 1,070.5)
cTnT, ng/mL 3.47 (0.26, 20.96) 0.91 (0.012, 11.88) 1.00 (0.031, 13.00)
Gensini scores 48.0 (38.4, 79.5) 44.5 (22, 73.4) 45.25 (22.75, 74.625)
LVEF, % 63 (60.75, 63.25) 63 (60, 64) 63 (60, 64)
History of stains use, n (%) 14 (46.7) 147 (52.3) 161 (51.8)
Last cardiovascular event time, day 2 (1, 2) 1 (1, 2) 1 (1, 2)

For continuous variables, normally distributed data were expressed as mean ± standard deviation (SD), while skewed data were described as median (interquartile range). For categorical, data were expressed as frequency counts. a, Student’s t test; b, Mann-Whitney U test; c, χ2 test. CAD, coronary artery disease; BMI, body mass index; T2DM, type 2 diabetes mellitus; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglyceride; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; WBC, white blood cell counts; NEU, neutrophil counts; LYM, lymphocyte counts; MON, monocyte counts; PLT, platelet counts; CRP, c-reaction protein; NT-proBNP, N-terminal pro-brain natriuretic peptide; cTnT, cardiac troponin T; LVEF, left ventricular ejection fraction.